Bimekizumab-bkzx
Cold Chain RequiredFDA Approved
Description
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key cytokines driving inflammatory processes. It is used to treat plaque psoriasis.
Indications & Therapeutic Use
Plaque Psoriasis
Linked Diseases:
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Bimekizumab-bkzx
| Generic Name | Bimekizumab-bkzx |
| Brands | 1 brand available |
| Active Ingredient | Bimekizumab |
| Drug Class | Plaque Psoriasis |
| Manufacturer | UCB S.A. |
| Dosage Forms | Subcutaneous injection |
| Medical Code | L04AC18 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03564418 |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes